Company news

ABIONYX Pharma SA news in 2026

ABIONYX Pharma SA's news releases, calls and decks from 2026, newest first.

View company

ABIONYX Pharma Finalizes the Structuring of Its CER-001 Bioproduction Chain Through a Strategic Partnership with AXPLORA, Marking a Major Milestone Toward Its Potential Commercialization

October 26, 2026

ABIONYX Pharma and OLON Enter Into Strategic Manufacturing Partnership to Prepare CER-001 Biologic for Regulatory Approval and Commercial Supply

October 7, 2026

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

October 2, 2026

Information relative au nombre total de droits de vote et d’actions composant le capital social

October 1, 2026

ABIONYX Pharma annonce le règlement d’un amortissement anticipé conformément aux termes de son contrat de Financement Obligataire

October 1, 2026

ABIONYX Pharma Announces the Settlement of an Anticipated Amortization Payment in Accordance With the Terms of Its Bonds Financing Agreement

October 2, 2026

ABIONYX Pharma: Half Year Results 2026

September 23, 2026

ABIONYX Pharma Reaches Another Key Milestone in the Industrialization of CER-001 by Entering into a Strategic Partnership with TEXCELL (ABL Diagnostics) for the Viral Safety and Clearance of Biologics

September 10, 2026

ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the First Half of 2026

August 27, 2026

Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

August 4, 2026

ABIONYX Pharma: Half-Year Review of the Liquidity Agreement Entered into with TP ICAP (Europe) SA

July 6, 2026

ABIONYX Pharma is Scaling up Its Operations After Securing the Resources Needed to Achieve Its Goals and Is Embarking on a New Cycle of Value Creation in the Treatment of Severe Inflammation and Sepsis

June 30, 2026

ABIONYX Pharma Announces the Success of its Financing for a Total Maximum Amount of EUR 33 M

June 18, 2026

ABIONYX Pharma: Combined Annual Shareholders’ Meeting on June 30, 2026: Availability of preparatory documents and procedures for participation and voting

June 9, 2026

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

June 2, 2026

ABIONYX Pharma Provides an Update on Its Operations and Cash Position for the First Quarter of 2026

May 28, 2026

ABIONYX Pharma Launches Fully Secured Capital Increase with Preferential Subscription Rights and Structured Debt Financing for an Aggregate Amount of up to c. EUR 33 M

May 27, 2026

ABIONYX Pharma Achieves Major Milestone in apoA-I Biomanufacturing with Breakthrough in Synthetic Sphingomyelin Production

March 27, 2026

ABIONYX Pharma: Availability of the Universal Registration Document for the year 2025

March 17, 2026

ABIONYX Pharma Announces Its 2025 Annual Results

March 12, 2026

ABIONYX Pharma Provides an Update on Its Business and Cash Position for the 4th Quarter of 2025

February 26, 2026

ABIONYX Pharma Announces Its Financial Calendar for the Year 2026

January 23, 2026

ABIONYX Pharma: Half-Yearly Report on the Liquidity Contract with TP ICAP (Europe) SA

January 7, 2026

Decks in 2026